UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 402

Sortiert nach

T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update

Journal of clinical medicine, 2023-10, Vol.12 (21), p.6737

2023

Link zum Volltext

Verfügbarkeit prüfen

Magnetoencephalography Studies of the Envelope Following Response During Amplitude-Modulated Sweeps: Diminished Phase Synchrony in Autism Spectrum Disorder

Frontiers in human neuroscience, 2021-12, Vol.15, p.787229-787229

2021

Link zum Volltext

Verfügbarkeit prüfen

Delayed M50/M100 evoked response component latency in minimally verbal/nonverbal children who have autism spectrum disorder

Molecular autism, 2019-08, Vol.10 (1), p.34-34, Article 34

2019

Link zum Volltext

Verfügbarkeit prüfen

Acquired Pure Red Cell Aplasia Associated with Chronic Myelomonocytic Leukemia: Too Many of One, Not Enough of the Other

Case reports in oncology, 2020-10, Vol.13 (3), p.1270-1274

2020

Link zum Volltext

Verfügbarkeit prüfen

Maturation of auditory neural processes in autism spectrum disorder - A longitudinal MEG study

NeuroImage clinical, 2016-01, Vol.11 (C), p.566-577

2016

Link zum Volltext

Verfügbarkeit prüfen

Delayed Auditory Evoked Responses in Autism Spectrum Disorder across the Life Span

Developmental neuroscience, 2019-01, Vol.41 (3-4), p.223-233

2019

Link zum Volltext

Verfügbarkeit prüfen

Multimodal Diffusion-MRI and MEG Assessment of Auditory and Language System Development in Autism Spectrum Disorder

Frontiers in neuroanatomy, 2016-03, Vol.10, p.30-30

2016

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of an online cognitive rehabilitation programme in patients with a haematological malignancy undergoing autologous stem cell transplantation

Internal medicine journal, 2021-10, Vol.51 (10), p.1665-1672

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

The lancet oncology, 2022-08, Vol.23 (8), p.1055-1065

2022

Link zum Volltext

Verfügbarkeit prüfen

Addition of low dose acetazolamide as an adjunct in patients undergoing high dose methotrexate is safe and beneficial

Internal medicine journal, 2020-03, Vol.50 (3), p.357-362

2020

Link zum Volltext

Verfügbarkeit prüfen

An extended release ciprofloxacin/dexamethasone hydrogel for otitis media

International journal of pediatric otorhinolaryngology, 2020-11, Vol.138, p.110311-110311, Article 110311

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS7575-TPS7575

2021

Link zum Volltext

Verfügbarkeit prüfen

Toxicity associated with high-dose intravenous methotrexate for hematological malignancies

Leukemia & lymphoma, 2022-08, Vol.63 (10), p.2375-2382

2022

Link zum Volltext

Verfügbarkeit prüfen

Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab

Blood reviews, 2017-01, Vol.31 (1), p.23-35

2017

Link zum Volltext

Verfügbarkeit prüfen

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

Clinical cancer research, 2022-09, Vol.28 (18), p.4003-4017

2022

Link zum Volltext

Verfügbarkeit prüfen

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Journal of clinical oncology, 2023-12, Vol.41 (35), p.5376-5387

2023

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Blood, 2022-11, Vol.140 (Supplement 1), p.9413-9415

2022

Link zum Volltext

Verfügbarkeit prüfen

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood, 2022-11, Vol.140 (Supplement 1), p.3728-3730

2022

Link zum Volltext

Verfügbarkeit prüfen

Abnormal maturation of the resting‐state peak alpha frequency in children with autism spectrum disorder

Human brain mapping, 2019-08, Vol.40 (11), p.3288-3298

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 402

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(360)
Mit Volltextzugriff
(350)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(402)
Japanisch
(52)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(29)
Clinical Lymphoma, Myeloma And Leukemia
(13)
Journal Of Clinical Oncology
(11)
Neuro-Oncology
(11)
American Journal Of Kidney Diseases
(10)
Internal Medicine Journal
(8)
Clinical Cancer Research
(6)
Leukemia & Lymphoma
(6)
Cancer Research
(5)
Circulation
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update

Magnetoencephalography Studies of the Envelope Following Response During Amplitude-Modulated Sweeps: Diminished Phase Synchrony in Autism Spectrum Disorder

Delayed M50/M100 evoked response component latency in minimally verbal/nonverbal children who have autism spectrum disorder

Acquired Pure Red Cell Aplasia Associated with Chronic Myelomonocytic Leukemia: Too Many of One, Not Enough of the Other

Maturation of auditory neural processes in autism spectrum disorder - A longitudinal MEG study

Delayed Auditory Evoked Responses in Autism Spectrum Disorder across the Life Span

Multimodal Diffusion-MRI and MEG Assessment of Auditory and Language System Development in Autism Spectrum Disorder

P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY

Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project

P1117: GLOFITAMAB PLUS R‐CHOP OR POLATUZUMAB VEDOTIN‐R‐CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH‐RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY

P1193: POLATUZUMAB, BENDAMUSTINE & RITUXIMAB (POLA‐BR) EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RRDLBCL) TRIAL‐INELIGIBLE PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY

Feasibility of an online cognitive rehabilitation programme in patients with a haematological malignancy undergoing autologous stem cell transplantation

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Addition of low dose acetazolamide as an adjunct in patients undergoing high dose methotrexate is safe and beneficial

An extended release ciprofloxacin/dexamethasone hydrogel for otitis media

A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Toxicity associated with high-dose intravenous methotrexate for hematological malignancies

Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Abnormal maturation of the resting‐state peak alpha frequency in children with autism spectrum disorder

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Suchergebnisse filtern